Wharton's jelly (WJ) and amniotic fluid (AF) are more primitive that adult mesenchymal stem cells (MSC), but not tumorigenic.
Preclinical and clinical studies suggest the safe and efficacious use of WJ-MSCs and AF-MSCs in future stem cell therapies.
WJ-MSCs and AF-MSCs are regenerative due to their migration, differentiation, secretome and immunomodulatory properties.